Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treatment. This study evaluated the 24-h bronchodilator efficacy of indacaterol in Japanese patients with asthma. Methods: Randomised, placebo-controlled, 5-period crossover study. Patients with persistent asthma (18e75 years, FEV 1 50e85% predicted, 12% and 200 mL FEV 1 reversibility) receiving ICS were randomised to double-blind single dose indacaterol 150, 300, or 600 mg or placebo, with open-label salmeterol 50 mg twice-daily for one day in the 5 th period. Primary endpoint was FEV 1 AUC 22e24h . Results: Of 41 randomised patients (48.8% male; mean age: 47.8 years), 39 completed. All indacaterol doses showed significantly higher FEV 1 AUC 22e24h than placebo (P < 0.001), with treatmenteplacebo differences of 180, 220, and 260 mL for indacaterol 150, 300, and 600 mg, respectively (salmeteroleplacebo difference 170 mL; P < 0.001). (P < 0.001). Compared with salmeterol, all indacaterol doses were superior from 5 to 30 min (P < 0.05); in addition indacaterol 300 mg and 600 mg were superior at a number of subsequent time points. Changes in safety parameters with indacaterol were similar to placebo. All indacaterol doses were well tolerated. Conclusion: Single dose indacaterol provided sustained 24-h bronchodilation with a faster onset of action than salmeterol and a good overall safety and tolerability profile in Japanese patients with asthma. These results are consistent with data from Caucasian populations. ª
Introduction
Worldwide, asthma affects people of all ages causing substantial debilitating symptoms and leading to a reduced quality of life. 1, 2 Evidence from most studies, including longitudinal surveys, suggests that the prevalence of asthma has increased over the past decades in many parts of the world, including Japan.
3e7 Persistent asthma is most effectively controlled with inhaled corticosteroids (ICSs) administered daily on a long-term basis. 8 For patients with asthma not adequately controlled with a low-dose ICS alone, current treatment guidelines recommend the addition of a long-acting beta-2 agonist (LABA) to the existing ICS therapy. 7e10 The goal of asthma management is to achieve and maintain control of symptoms e a major obstacle to which has been low patient adherence to medication plans. 11 A key factor contributing to poor adherence is a complicated or multiple treatment regimen, with simplified dosing regimens known to improve compliance. 11, 12 Currently available inhaled LABAs (e.g., salmeterol and formoterol) have an approximately 12-h duration of action, necessitating twicedaily (bid) dosing to provide optimal clinical efficacy. 13, 14 Thus the availability of a once-daily beta-2 agonist with a 24-h duration of action combined with a once-daily ICS could improve clinical outcomes in asthma by providing increased patient convenience and sustained bronchodilation.
Indacaterol is a novel, once-daily, inhaled, ultra-LABA under development as a fixed-dose combination with ICS for the treatment of asthma. In preclinical studies, indacaterol demonstrated a sustained bronchodilator and bronchoprotective effect, with a fast onset of action (comparable to salbutamol and formoterol) and greater cardiovascular safety margin than formoterol or salmeterol. 15, 16 Furthermore, in earlier clinical studies involving mostly the Caucasian population, indacaterol showed effective 24-h bronchodilation, with a fast onset of action and a good overall safety and tolerability profile. 17e21 The present dose-ranging study was the first to investigate the 24-h bronchodilatory efficacy and safety of single doses of indacaterol 150, 300, and 600 mg delivered via a single-dose dry-powder inhaler (SDDPI) in Japanese patients with asthma. Given its similarity to a study conducted in a Caucasian population it helps to evaluate the ethnic sensitivity of the efficacy and safety of indacaterol. 21 
Methods
This was a Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover, dose-ranging study conducted between November 2006 and November 2007 at 11 specialised allergy and respiratory care units in Japan (ClinicalTrials.gov registration no.: NCT00403754). 22 The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. The study was approved by the institutional review board of each participating study centre, and all patients provided written informed consent before participating in the study.
Study population
The study recruited Japanese patients (aged 18e75 years) with a clinical diagnosis of asthma according to the 2006 Japanese asthma prevention and management guideline 7 (FEV 1 between 50% and 85% of the predicted normal value at screening, with 12% and 200 mL reversibility in FEV 1 within 30 min after inhalation of salbutamol 200 mg). In addition, patients must have received daily ICS treatmentddefined as fluticasone propionate 200e800 mg (or equivalent)din a stable regimen for at least 4 weeks before the screening visit (Visit 1).
Patients were excluded if they underwent hospitalization or emergency room treatment for an acute exacerbation of asthma in the 6 months before Visit 1, had respiratory disease other than asthma, had respiratory tract infection within 4 weeks before Visit 1, used tobacco products within 6 months before Visit 1, or had a smoking history of more than 10 pack-years. The other exclusion criteria included seasonal allergies that might cause deterioration of asthma; allergy to beta-2 agonists, sympathomimetics, and inhaled medications; ischemic heart disease; arrhythmia; uncontrolled hypertension; type 1 diabetes; cancer; and a prolonged QT interval.
Study design and treatments
The study comprised a 14-day screening period, four double-blind treatment periods (Visits 2e9), and an openlabel treatment period (Visits 10 and 11) (Fig. 1) . The visits on Day 1 and Day 2 of each treatment period were on consecutive days. Following screening, all eligible patients were randomised equally (at Visit 2), using a validated automated system, to one of four treatment sequences to receive a single dose of indacaterol 150, 300, and 600 mg or placebo via an SDDPI. Patients who completed the doubleblind treatment period entered a single-day, open-label treatment period with salmeterol 50 mg bid delivered via the manufacturer's proprietary multidose dry-powder inhaler.
During the double-blind treatment periods, the study drug was inhaled between 08:00 and 10:00 AM on Day 1 (Visits 2, 4, 6, and 8). During the open-label period (Visit 10), the first salmeterol dose was inhaled between 08:00 and 10:00 AM, and the second dose was inhaled after spirometry at 12 h post-dose. Each treatment period was separated by a 14e28 day washout period. Treatment allocation was concealed from the patients, investigating staff, and the clinical trial team by using study drugs that were identical in packaging, labelling, appearance, and administration schedule.
Concomitant medication
Other than ICS in a fixed-dose regimen that had been stabilised for at least 4 weeks prior to Visit 1 with the ICS dose remaining unchanged throughout the study, the following asthma treatments were allowed between the treatment periods (following the same regimen as the one before Visit 1): short-acting beta-2 agonists (6 h), LABAs (48 h), xanthine derivatives (7 days), leukotriene antagonists (72 h), and short-acting anticholinergics (8 h). These treatments, however, had to be discontinued no later than the specified time (mentioned within the parentheses above) before Visits 1, 2, 4, 6, 8, and 10, and were not to be recommenced until the completion of the last spirometry evaluations at Visits 3, 5, 7, 9, and 11. Salbutamol was the only rescue medication permitted throughout the study, although visits had to be rescheduled if it was taken within 6 h prior to the first spirometry measurements during that visit.
Assessments
Efficacy and safety were assessed for 24 h post-dose in each treatment period. Efficacy was assessed by spirometry using the same model of spirometer at all sites (MICROSPIRO HI-201 Ò , Nihon Kohden Corporation, Tokyo, Japan). . By using data from up to three time points, this endpoint (which can be considered an average of data from the three evaluations) has the advantage of a smaller standard deviation compared with a single time point, and provides more power for a given number of patients. Further, since data forming this endpoint are from the end of the dosing interval, this endpoint should capture the lowest measured treatmenteplacebo differences. Secondary efficacy outcomes included percent change in FEV 1 from baseline at each individual time point post-dose; peak FEV 1 (defined as the maximum FEV 1 value recorded between 5 min and 4 h postdose); standardised FEV 1 AUC 0e24h ; and individual time point FEV 1 , FVC, and FEF 25e75% .
Safety assessments involved recording of all adverse events (AEs) and serious adverse events (SAEs) in all treatment periods. The occurrence of AEs was sought by non-directive questioning of patients at each visit during the study, and may also have been detected when volunteered by patients during or between visits or through physical examination, laboratory test, or other assessments. In addition, during the double-blind treatment periods, safety was assessed by monitoringdat regular time points in each treatment perioddof haematology and blood biochemistry (including serum potassium and blood glucose); urinalysis; and regular assessments of vital signs and ECGs. During the open-label treatment period, with the exception of adverse events no other safety data was collected.
Sample size calculation and statistical analyses
The three main treatment comparisons were indacaterol 150 mg versus placebo, indacaterol 300 mg versus placebo, and indacaterol 600 mg versus placebo. The sample size calculation was based on the post-dose primary efficacy variable, standardised FEV 1 AUC 22e24h . A standard deviation (SD) of 283 mL, 23 reversibility threshold of 12%, two-sided significance level of 10% (adjusted to 3.3% using a Bonferroni correction for the three main treatment comparisons), and power of 85% were chosen for the sample size calculation. Assuming a drop out rate of 15% and to ensure balance across the treatment sequences, 40 patients were to be randomised in order to have at least 32 patients completing the study.
The primary efficacy analysis was performed on a modified intention-to-treat (mITT) population, which included all randomised patients who received at least one dose of the study drug. Patients receiving only one treatment did not contribute to the analyses of treatment contrasts but remained in the population for the calculation of treatment means. The safety population included all patients who received at least one dose of the study drug and was used in the analysis of all safety variables. For both populations, the patients were analysed according to the treatment they received.
For the primary efficacy variable, standardised FEV 1 AUC 22e24h , treatment differences between each indacaterol dose and placebo were tested using analysis of covariance (ANCOVA), with patient, period, and treatment group modelled as fixed effects and period baseline FEV 1 as a covariate. Adjustment for multiple comparisons was made using a stepwise Dunnett test. ANCOVA models were also used to analyse all the secondary efficacy variables. ANCOVA models were also used to provide between-indacaterol-dose comparisons and comparisons with salmeterol; however, these analyses were regarded as exploratory, because the study was not powered for comparisons between the active treatment groups. The corrected QT (QTc) interval was calculated from the QT and RR intervals using Fridericia's formula (QTcF). 24 All tests of hypotheses used were twotailed and interpreted at the 10% significance level (as this was a dose-finding study). The data were analysed using SAS statistical software version 8.1 (or higher) for Windows (SAS Institute Inc., Cary, NC, USA).
Results

Patient disposition, demographics, and baseline characteristics
Of 93 screened patients, 41 were randomised to treatment. Out of the 41 randomised patients, 39 (95.1%) completed the study. Two patients (4.9%) discontinued, one due to unsatisfactory therapeutic effect after the second treatment period (having received indacaterol 300 mg and placebo) and the other withdrew consent after the first treatment period (having received indacaterol 150 mg). Table 1 shows the demographics and baseline characteristics of the patients in the study, all of whom were Japanese.
Efficacy
Indacaterol at all doses resulted in a statistically superior (P < 0.001) adjusted mean standardised FEV 1 AUC 22e24h compared to placebo (Fig. 2) , with treatmenteplacebo differences of 180 (90% CI: 120, 250), 220 (150, 280), and 260 (190, 320) mL for the 150, 300, and 600 mg doses, respectively, compared with a salmeteroleplacebo difference of 170 (120, 220) mL. At all time points from 5 min to 24 h post-dose, all indacaterol doses showed statistically significant differences (P < 0.001) in the adjusted mean FEV 1 as compared with placebo ( Fig. 3) . In addition, all doses of indacaterol were statistically superior (P < 0.05) to salmeterol from 5 min to 30 min postdose. Indacaterol resulted in a significantly greater peak FEV 1 compared with placebo (P < 0.001) and numerically (150 and 300 mg) or statistically (600 mg) higher peak FEV 1 compared with salmeterol 50 mg bid. All indacaterol doses resulted in significantly higher (P < 0.001) adjusted mean FEV 1 AUC 0e24h than placebo with treatmenteplacebo differences of 220 (90% CI: 170, 270) mL, 270 (220, 320) mL, and 310 (260, 360) mL for the 150, 300, and 600 mg doses, respectively, and a salmeteroleplacebo difference of 200 (150, 240) mL. When compared with salmeterol, the standardised FEV 1 AUC 0e24h was significantly greater with indacaterol 600 mg (110 mL; P < 0.001) and 300 mg (80 mL; P Z 0.0096), and numerically higher with indacaterol 150 mg (30 mL; P Z 0.34). All indacaterol doses showed significantly higher FVC, FEF 25e75% , and percent change from period baseline in FEV 1 than placebo at all post-dose time points (P < 0.002), with profiles similar to those observed for FEV 1 (data not shown). Indacaterol also showed higher FVC, FEF 25e75% , and percent change from period baseline in FEV 1 than salmeterol at the majority of the post-dose time points.
Safety
Indacaterol doses were well tolerated, with no deaths or SAEs reported. The overall incidence of AEs during the double-blind treatment phase was 27.5% (11/40), 45.0% (18/40), 40.0% (16/40), and 56.4% (22/39) for placebo and indacaterol 150, 300, and 600 mg, respectively ( Table 2) . The most commonly reported AE with indacaterol treatment was cough, which was mostly mild in severity and transient in nature, occurring just after inhalation of the study drug. reported with three patients following indacaterol 300 mg and one patient following 600 mg, none of which were, however, associated with AEs (Table 3) . As summarised in Table 3 , the incidence of abnormal values for pulse rate (>90 bpm) and diastolic (>90 mm Hg) and systolic (>140 mm Hg) blood pressure was similar between placebo and the indacaterol treatments, indicating no relationship with indacaterol dose. No clinically significant ECG abnormalities and no abnormal QTcF prolongation (male: QTcF >450 ms; female: >470 ms) or change in QTcF from baseline (>60 ms) were observed with any of the treatments (Table 4) .
Discussion
This was the first study to evaluate the 24-h bronchodilator efficacy of single doses of indacaterol 150, 300, and 600 mg in Japanese patients with asthma. This crossover study showed that indacaterol provided sustained 24-h bronchodilation, with a fast onset of action and a good overall safety and tolerability profile. A crossover design was preferred because variations in FEV 1 within patients were expected to be less compared with variations in FEV 1 between patients.
In the present study, the primary efficacy analysis showed that all indacaterol doses were associated with statistically significantly greater (P < 0.001) standardised FEV 1 AUC 22e24h than placeboda finding consistent with a previous dose-ranging study. 19 Furthermore, the corresponding 90% CIs of the differences between the indacaterol doses and placebo were relatively narrow, indicating the precision of the estimated differences. In terms of comparisons between indacaterol doses, the 600 mg dose was statistically superior to the 150 mg dose for this endpoint, whereas there was no statistically significant difference between indacaterol 150 and 300 mg. In previous studies in patients with asthma in which indacaterol was administered at a dose of 50e600 mg, there were similar separations in efficacy between the lowest and highest indacaterol dose.
19e21, 23, 25 The current study would suggest that, given the similar efficacy to salmeterol, 150 mg could be the minimal effective dose of indacaterol in asthma e this would, however, need confirming in a more comprehensive dose-finding study. The results of the primary analysis of this study was supported by those of the secondary efficacy analyses, demonstrating that all three indacaterol doses had statistically significant higher peak FEV 1 and standardised FEV 1 AUC 0e24h compared with placebo (P < 0.001). In addition, all indacaterol doses showed notable improvements in FEV 1 at nearly all time points over 24 h compared with placeboda finding also consistent with earlier studies conducted mostly on the Caucasian population.
18e21, 25 These results, together with the 24-h profiles of FVC and FEF 25e75% , indicate that indacaterol provided effective and sustained 24-h bronchodilation, which further supports the potential for a once-daily dosing regimen. Given the similar efficacy demonstrated by indacaterol in Japanese and Caucasian patients, this is an indication that indacaterol is likely to be effective in the management of asthma regardless of a patient's ethnicity. This is an important consideration for any bronchodilator, given there is an evidence of divergence in beta-2 adrenoceptor polymorphism haplotype frequency in the ethnic groups 26 In addition, several studies have investigated the polymorphisms of beta-2 adrenoceptor with regard to the bronchodilator response to inhaled beta-2 agonists. 27, 28 However, in clinical studies investigating the use of LABAs in COPD patients, there are several reports that demonstrate similar response in Japanese and Caucasian populations. 29, 30 In previous studies in the Caucasian population, indacaterol has shown a fast onset of action, similar to that of salbutamol (a short-acting beta-2 agonist) and faster than salmeterol. 18 The results of our study are also consistent with these findings, as significant improvements in FEV 1 appeared as early as 5 min post-indacaterol dose (the earliest time point evaluated), with all indacaterol doses showing statistical superiority (P < 0.05) to salmeterol until at least 30 min post-dose.
The convenience of once-daily dosing together with sustained bronchodilation and a fast onset of action could potentially enable enhanced patient compliance and asthma control compared with twice-daily therapies. 20 Thus indacaterol, when combined with a once-daily ICS, could have an advantage in terms of patient acceptability, convenience, and adherence to therapy. These aspects of indacaterol treatment could not be assessed in the current study, given the single-day dosing study design. Furthermore, salmeterol was administered on an open-label basis in the final treatment period for all patients. This was for practical purposes, and made the study design less complex (with only one type of placebo inhaler required), and it should be noted that the primary comparison was between indacaterol and placebo. However, the inclusion of a LABA active comparator is helpful in the interpretation of the study results.
All indacaterol doses in the present study were well tolerated and showed a good overall safety profile. No patient treated with indacaterol discontinued the study due to AEs. Most AEs reported in this study were expected in this patient population and were similar to those observed in previous studies conducted outside Japan. 17, 18, 20, 31 The incidence of AEs reported in this study was higher with indacaterol treatment than with openlabel salmeterol (which was taken by all patients during the final treatment period). This difference in the rate of AEs was due to the higher incidence of cough in patients treated with indacaterol. The majority of cough AEs were mild in severity, occurred just after inhalation of study drug and were transient in nature. Notably, recording of AEs was the only safety assessment performed for salmeterol.
No deaths or SAEs were reported in this study. Given the class effects of beta-2 agonists on serum potassium and blood glucose, these parameters were analysed extensively, and there was no clear relationship between the incidence of hypokalaemia or hyperglycaemia and the indacaterol doses. Furthermore, no major effect on the QT interval and pulse rate was observed with the indacaterol doses.
The overall safety and tolerability profile of indacaterol was consistent with the previous studies that involved repeated indacaterol doses for up to 28 days. 17, 27 Further studies investigating the long-term efficacy and safety of indacaterol in a fixed-dose combination with an ICS are planned.
In conclusion, single doses of indacaterol 150, 300, and 600 mg in combination with an ICS provided superior bronchodilation for 24-h with a faster onset of action compared with salmeterol 50 mg bid in combination with an ICS in Japanese patients with asthma. In addition, indacaterol demonstrated a good overall safety and tolerability profile in this patient population. Therefore, the development of indacaterol in conjunction with an ICS could be a useful treatment option for Japanese patients with asthma.
